TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ:TNXP) Files An 8-K Other Events
Item 8.01
| Other Events. |
On December 7, 2016, Tonix Pharmaceuticals Holding Corp. (the
Company) will present a poster entitled The AtEase Study: A
Phase 2 Multicenter Randomized Clinical Trial of the Safety and
Efficacy of TNX-102 SL in the Treatment of Military-Related
PTSD (the Poster), at the 55th Annual Meeting of
the American College of Neuropsychopharmacology being held in
Hollywood, Florida. The Poster will be presented by Dr. Gregory
Sullivan, M.D., Chief Medical Officer of the Company. This Poster
replaces the prior version of a poster that the Company filed on
a Form 8-K on December 2, 2016.
The foregoing description of the Poster is qualified in its
entirety by reference to the Poster, a copy of which is filed as
Exhibit99.01 to, and is incorporated by reference in, this
report.
The information in this Current Report is being furnished and
shall not be deemed filed for the purposes of Section 18 of the
Securities Exchange Act of 1934 or otherwise subject to the
liabilities of that Section. The information in this Current
Report shall not be incorporated by reference into any
registration statement or other document to the Securities Act of
1933, except as shall be expressly set forth by specific
reference in any such filing.
| Item 9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits. |
| 99.01 |
The AtEase Study: A Phase 2 Multicenter Randomized Clinical Trial of the Safety and Efficacy of TNX-102 SL in the Treatment of Military-Related PTSD Poster* |
* Furnished herewith.
About TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ:TNXP)
TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ:TNXP) Recent Trading Information
TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ:TNXP) closed its last trading session down -0.002 at 0.390 with 870,740 shares trading hands.
